Featured Publications
The spectrum of cutaneous immune-related adverse events in patients with skin of color
Belzer A, Mortlock R, Olamiju B, Olino K, Cohen J, Leventhal J. The spectrum of cutaneous immune-related adverse events in patients with skin of color. Journal Of The American Academy Of Dermatology 2022, 88: 1156-1158. PMID: 36470309, PMCID: PMC10838520, DOI: 10.1016/j.jaad.2022.11.051.Peer-Reviewed Original ResearchThe effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy
Belzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.Peer-Reviewed Original ResearchAssessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology
Mortlock R, Ma E, Cohen J, Damsky W. Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology. Journal Of Investigative Dermatology 2023, 143: 1412-1422. PMID: 37341663, PMCID: PMC10830170, DOI: 10.1016/j.jid.2023.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAtopic dermatitisSkin diseasesInflammatory skin diseaseInflammatory skin conditionImmunologic biomarkersImmune biomarkersPersonalized medicineInflammatory dermatosesImmunologic approachesTherapy selectionSkin conditionsSingle-cell RNA sequencingMolecular profilingBiomarkersTissue stainingPsoriasisDermatitisDiseaseDermatologyRNA sequencingMedicineCurettageDermatosesTherapyPersonalized classification
2024
Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys
Piotrowski-Daspit A, Bracaglia L, Eaton D, Richfield O, Binns T, Albert C, Gould J, Mortlock R, Egan M, Pober J, Saltzman W. Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys. Nature Communications 2024, 15: 4247. PMID: 38762483, PMCID: PMC11102454, DOI: 10.1038/s41467-024-48442-7.Peer-Reviewed Original ResearchConceptsPoly(amine-co-esterPolymer nanoparticlesDelivery of nucleic acid therapeuticsCell-type tropismTissue tropismNucleic acid delivery vehiclesIn vivo deliveryIn vivo efficacyCirculation half-lifeNucleic acid therapeuticsVehicle characteristicsTunable propertiesBiodistribution assessmentPhysiological fatePolymer chemistrySurface propertiesPharmacokinetic modelTissue targetingNanoparticlesDistribution modifiersPolymeric nanoparticlesTropismPolymerDelivery vehiclesHalf-life
2023
Early observations with an ERAS pathway for thyroid and parathyroid surgery: Moving the goalposts forward
Machado N, Mortlock R, Maduka R, Souza Cunha A, Dyer E, Long A, Canner J, Tanella A, Gibson C, Hyman J, Ogilvie J. Early observations with an ERAS pathway for thyroid and parathyroid surgery: Moving the goalposts forward. Surgery 2023, 175: 114-120. PMID: 37973430, PMCID: PMC10838521, DOI: 10.1016/j.surg.2023.06.052.Peer-Reviewed Original ResearchConceptsSurgery pathwayEnhanced recoverySurgery groupParathyroid surgerySignificant decreasePost-anesthesia care unit lengthAverage daily pain scoreSuperficial cervical plexus blockThyroid/parathyroid surgeryAverage daily morphineDaily pain scoresCervical plexus blockCases 1 yearStandard of careDaily morphineERAS pathwayPostoperative admissionPostoperative antiemeticsPostoperative morphineUnanticipated admissionPain scoresPerioperative outcomesPlexus blockProspective trialPatient group